[Federal Register: April 28, 2003 (Volume 68, Number 81)]
[Notices]               
[Page 22391]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28ap03-67]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

 
Dental Products Panel of the Medical Devices Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Dental Products Panel of the Medical Devices 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on May 22, 2003, from 9:30 
a.m. to 4:30 p.m.
    Location: Gaithersburg Holiday Inn, Walker/Whetstone Rooms, Two 
Montgomery Village Ave., Gaithersburg, MD.
    Contact Person: Michael E. Adjodha, Center for Devices and 
Radiological Health (HFZ-480), Food and Drug Administration, 9200 
Corporate Blvd., Rockville, MD 20850, via e-mail at mea@cdrh.fda.gov, 
or by phone: 301-827-5283, ext. 123. Please call the FDA Advisory 
Committee Information Line at 800-741-8138 (301-443-0572 in the 
Washington, DC area), code 12518, for updated information on this 
meeting.
    Agenda: The committee will discuss, make recommendations, and vote 
on a petition to reclassify tricalcium phosphate granules for dental 
bone repair (21 CFR 872.3930) from class III to class II (special 
controls). Background information, including the agenda and questions 
for the committee, will be available to the public 1 business day 
before the meeting on the Internet at http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/cdrh/panelmtg.html.
 Material will be posted on May 21, 2003.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by May 7, 2003. 
Oral presentations from the public will be scheduled for approximately 
60 minutes at the beginning of committee deliberations. Time allotted 
for each presentation may be limited. Those desiring to make formal 
oral presentations should notify the contact person before May 7, 2003, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Closed committee deliberations: On May 22, 2003, from 4 p.m. to 
4:30 p.m., the meeting will be closed to the public to permit FDA to 
present to the committee trade secret and/or confidential commercial 
information regarding pending and future agency issues (5 U.S.C. 
552b(c)(4)).
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact AnnMarie Williams, 
Conference Management Staff, 301-594-1283, ext. 113, at least 7 days in 
advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: April 21, 2003.
Peter J. Pitts,
Associate Commissioner for External Relations.
[FR Doc. 03-10299 Filed 4-25-03; 8:45 am]

BILLING CODE 4160-01-S